CRESCENDO BIOLOGICS
Live / Registered — Registered — Section 71 accepted (as of 24 Apr 2025)
What this means for you
Registered since 12 Jun 2018. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79209645
- Registration number
- 5488713
- Mark type
- Design + words
- Filed
- 21 Oct 2016
- Published for opposition
- 27 Mar 2018
- Registered
- 12 Jun 2018
- Attorney of record
- Christopher J. Schulte
Goods and services
- Class 001 — Chemicals: Chemicals used in industry and science; [ chemicals for laboratory research purposes, namely, chemical tests kits for in vitro testing; ] antibodies and antibody fragments for scientific and laboratory use in the nature of biochemical, namely, monoclonal antibodies for in vitro scientific or research use; biochemical, namely, monoclonal antibodies and antibody fragments for scientific and laboratory use; antibodies and antibody fragments all being protein in raw material form for scientific research purposes; antibody reagents used for the detection of antigens in cell and tissue analysis for scientific and laboratory in vitro diagnostic use; antibodies and antibody fragments all being proteins for industrial use in the discovery, preclinical and clinical development of therapeutic products
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of cancer, [ autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; ] veterinary preparations for the treatment of cancer, [ autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; ] therapeutic preparations in the nature of antibodies and antibody fragments for medical and veterinary purposes, namely, therapeutic pharmaceutical preparations for the treatment of cancer, [ autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; ] antibodies, being pharmaceutical preparations for the treatment of cancer, [ autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; ] monoclonal antibody therapies for therapeutic purposes, being pharmaceutical preparations for the treatment of cancer, [ autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; ] antibodies and antibody fragments, being pharmaceutical preparations for the treatment of cancer, [ autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, for medical and veterinary diagnostics; antibodies and antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, for use in the discovery, preclinical and clinical development of therapeutic products; antibodies and antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, ] for use in the manufacture of therapeutic products
- Class 040 — Treatment of materials: Treatment and transformation of materials for others, namely the custom manufacture of chemicals, biologicals, antibodies and antibody fragments; contract manufacturing services in the field of chemicals, biologicals, antibodies and antibody fragments; services for the custom manufacture of medical therapies using antibodies and antibody fragments
Owner
- Crescendo Biologics Limited, Cambridge, GB
- Crescendo Biologics Limited, GB
- Crescendo Biologics Limited, GB
Prosecution history
- 24 Dec 2025 — PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
- 03 Jun 2025 — LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
- 24 Apr 2025 — NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
- 24 Apr 2025 — REGISTERED-SEC.71 ACCEPTED
- 21 Apr 2025 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 04 Dec 2024 — TEAS SECTION 71 RECEIVED
- 08 Nov 2024 — RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
- 27 Oct 2023 — LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
- 19 Aug 2023 — RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
- 12 Jun 2023 — COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
- 06 Oct 2018 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 18 Sept 2018 — FINAL DISPOSITION NOTICE SENT TO IB
- 18 Sept 2018 — FINAL DISPOSITION PROCESSED
- 12 Sept 2018 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 12 Jun 2018 — REGISTERED-PRINCIPAL REGISTER